Glaucoma - Pipeline Insight, 2022

Glaucoma - Pipeline Insight, 2022

DelveInsight’s, “Glaucoma - Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Glaucoma Understanding

Glaucoma: Overview

Glaucoma is a group of eye diseases causing optic nerve damage. The optic nerve carries images from the retina, which is the specialized light sensing tissue, to the brain so we can see. In glaucoma, eye pressure plays a role in damaging the delicate nerve fibers of the optic nerve. When a significant number of nerve fibers are damaged, blind spots develop in the field of vision. Once nerve damage and visual loss occur, it is permanent. Most people don't notice these blind areas until much of the optic nerve damage has already occurred. If the entire nerve is destroyed, blindness results. Glaucoma is a leading cause of blindness in the world, especially in older people. Early detection and treatment by your ophthalmologist are the keys to preventing optic nerve damage and vision loss from glaucoma. The exact causes of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Although high eye pressure sometimes leads to glaucoma, many people can also develop glaucoma with ""normal"" eye pressure. The treatment for glaucoma depends upon the nature and severity of each case. In general, glaucoma cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. With any type of glaucoma, regular eye examinations are very important to detect progression and to prevent vision loss.

""Glaucoma - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glaucoma pipeline landscape is provided which includes the disease overview and Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Glaucoma.
• In the coming years, the Glaucoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Glaucoma treatment market. Several potential therapies for Glaucoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Glaucoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Glaucoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Glaucoma Emerging Drugs Chapters

This segment of the Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glaucoma Emerging Drugs

• QLS-101: Qlaris Bio, Inc.

QLS-101 is our lead program based upon research from the laboratory of Professor Michael Fautsch at Mayo Clinic. The original compounds were first synthesized at the laboratory of Professor Peter Dosa at the University of Minnesota. QLS-101 is a novel prodrug of a well-characterized ATP-sensitive potassium (KATP) channel modulator that lowers intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the Trabecular Meshwork, thereby reducing distal outflow resistance and lowering Episcleral Venous Pressure (EVP). QLS-101 has shown efficacy in lowering IOP across multiple preclinical animal species, including mice, rabbits, dogs, and non-human primates, as well as in human eye explants. To date, QLS-101 has been demonstrated to be well-tolerated with no observed hyperemia in the efficacious dose range. Qlaris Bio has initiated clinical studies with QLS-101 in patients with Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma, and Sturge-Weber syndrome.

• NCX 470: Nicox

NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog eye drop, designed to release bimatoprost and NO into the eye to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. NO is a well-known small naturally-occurring signaling molecule that plays a key role in the regulation of IOP through activation of soluble guanylate cyclase (sGC). Bimatoprost, marketed under the brand name LUMIGAN® by AbbVie, Inc., is one of the leading branded products in the class of prostaglandin analogs (PGAs). Prostaglandin analogs are the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension. Nitric oxide brings additional IOP-lowering efficacy by enhancing aqueous humor drainage from the eye via a different mechanism of action than that engaged by prostaglandin analogs. We believe a novel dual mechanism of action can achieve superior IOP-lowering compared to the parent compound alone. NCX 470 has the same mechanism-of-action as our first marketed product in the U.S. NCX 470 is currently in two multi-regional Phase 3 clinical trials, Mont Blanc and Denali, evaluating the IOP lowering efficacy of once-daily dosed NCX 470 ophthalmic solution 0.1% compared to latanoprost ophthalmic solution 0.005% in patients with open-angle glaucoma or ocular hypertension. Latanoprost, first marketed as Xalatan, is the most prescribed PGA in the U.S.

Further product details are provided in the report……..

Glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Glaucoma

There are approx. 70+ key companies which are developing the therapies for Glaucoma. The companies which have their Glaucoma drug candidates in the most advanced stage, i.e. phase III include, Nicox.

• Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glaucoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glaucoma drugs.

Glaucoma Report Insights

• Glaucoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Glaucoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Glaucoma drugs?
• How many Glaucoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glaucoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glaucoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glaucoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Qlaris Bio, Inc.
• Nicox
• Allysta Pharmaceutical
• ONL Therapeutics
• AbbVie
• JeniVision, Inc.
• Ocular Therapeutix
• Annexon, Inc.
• Laboratoires Thea
• Optifye Therapeutics
• PolyActiva
• Laboratorios Sophia S.A de C.V.
• pH Pharma
• Santen Pharmaceutical
• Peregrine Ophthalmic
• Envisia Therapeutics
• Tarsier Pharma
• Ocular Therapeutix
• Aerpio Therapeutics
• Whitecap Biosciences, LLC
• Chong Kun Dang Pharmaceutical
• MediPrint Ophthalmics, Inc.
• Noveome Biotherapeutics
• Novaliq GmbH
• Kowa
• D. Western Therapeutics Institute
• Sun Pharma Advanced Research Company
• GrayBug inc.
• Biozeus
• Ocuphire Pharma
• VISUS THERAPEUTICS
• Eyevensys
• Skye Bioscience inc
• Eyebiotech limited
• Stuart Therapeutics
• Q BioMed Inc.
• TALLC Inc.
• Mitotech
• Cloudbreak Pharmaceutical
• Cellix Bio
• Galimedix Therapeutics

Key Products

• QLS-101
• NCX 470
• H-1337
• CKD-351
• Visomitin
• D930
• GAL-101
• CLX-OPH-56
• CBT-007
• TA-A002
• VT-1041
• LL-BMT1
• Nyxol
• PDP – 716
• BZ371A
• MAN-01
• D565
• K-232
• ONL1204
• AGN-193408
• H-1337
• WB007
• AKB-9778
• OTX-TIC
• JV-GL1
• OTX-TPa
• ENV515-3
• ANX007
• T-4032
• Bimatoprost PF
• BTQ 1901 / BTQ 1902
• PA5108
• PRO-122
• PHP-201
• DE-126
• POLAT-001
• TRS01
• ST266
• GB-401


Please Note: It will take 7-10 business days to complete the report upon order confirmation.